NuvaRing Lawsuit Alleges Merck & Co., Organon USA, Inc., and other Defendants Failed to Warn Plaintiff of Serious NuvaRing Side Effects, Such as a Higher Risk of Venous Thromboembolism, Including Deep Vein Thrombosis and Pulmonary Embolism, Compared to Oral Contraceptives.
Melville, NY (PRWEB) June 04, 2012
The leading law firm Alonso Krangle LLP, focused on fighting for the rights of serious personal injury victims of harmful drug side effects, announce their firm has filed a NuvaRing lawsuit on behalf of a woman from Iowa who suffered an acute pulmonary embolism, allegedly due to her use of the NuvaRing vaginal ring birth control device. The complaint, which was filed on May 30, 2012, in the U.S. District Court for the District of New Jersey, names Merck & Co. Organon USA, Inc., Organon Pharmaceuticals USA, Inc., N.V. Organon, Schering Plough Corporation and Akzo Nobel, NV as Defendants (Case No. 2:12-cv-03240-SDW-MCA).
Alonso Krangle is currently offering FREE NuvaRing lawsuit consultations to victims of alleged NuvaRing side effects, including:
- Venous Thromboembolism (Blood Clots)
- Deep vein thrombosis
- Pulmonary embolism
- Heart attacks
- Wrongful death
To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
According to the complaint filed by Alonso Krangle, LLP, the Plaintiff began using NuvaRing in May 2009, allegedly due to the Defendants’ claims regarding the safety and efficacy of the device. In June of 2010, the Plaintiff suffered an acute pulmonary emboli, allegedly due to her use of NuvaRing. The lawsuit claims that due to her direct and proximate use of NuvaRing, the Plaintiff has suffered serious injuries and continues with regular follow-up care, including examinations, appointments, and medications.
According to the lawsuit, NuvaRing is marketed as the first and only, once-a-month vaginal birth control ring. The Defendants claim NuvaRing is as effective at preventing pregnancy as other hormonal birth control methods, including birth control pills, but with more convenience because it offers “month long protection, so women who use NuvaRing don’t have to think about contraception every day.” The package insert accompanying NuvaRing stated that the vaginal ring is expected to be associated with similar risks to that of birth control pills. However, the lawsuit alleges that the NuvaRing package insert is misleading because the safety information provided to consumers was derived primarily from studies of birth control pills, and not primarily from studies of NuvaRing.
Among other things, the complaint alleges that the Defendants failed to warn of the extent of venous thromboembolism, including pulmonary embolism and deep vein thrombosis, associated with NuvaRing. Further, the lawsuit asserts that etonogestral, a synthetic, third generation progestin, which is used as a starter in NuvaRing, was not the subject of sufficient and adequate testing, and that the Defendants knew or should have known that information conveying certain adverse events, including deep vein thrombosis, pulmonary embolism, and death, should have been set forth in NuvaRing’s package insert.
Introduced in 2001, NuvaRing is a hormonal contraceptive device that releases a combination of etonogestrel, a synthetic generation progestin, and the estrogen, ethinyl estradiol. The small, flexible ring is designed to be inserted into the vagina once a month. It is kept in place for three weeks, and prevents pregnancy by releasing controlled amounts of those hormones into the bloodstream.
Last October, results from an FDA-funded study that involved 800,000 American women using some form birth control between 2001 and 2008 revealed using NuvaRing increased the risk of blood clots, including deep vein thrombosis and pulmonary embolism, by 56% in comparison to older birth control pills. The FDA study noted that combined hormonal contraceptives, including the etonogestrel/ethinyl estradiol vaginal ring, “potentially result in higher sustained exposure to estrogen and hence, increased thromboembolic risk.” CHC-CVD final report: Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease
A second study, published on May 10, 2012 in the online edition of the British Medical Journal, found that NuvaRing users had a 6.5 times higher risk of experiencing a serious blood clot compared to women who did not use any form of hormonal birth control. The likelihood of experiencing a dangerous blood clot was 90% higher among users of the vaginal ring than it was for women taking combined oral contraceptives containing levonorgestrel. BMJ: Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Hundreds of NuvaRing lawsuits alleging the device caused serious side effects, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes and wrongful death are currently pending in a multidistrict litigation before Rodney W. Sippel of the U.S. District Court, Eastern District of Missouri (MDL No. 1964). Additional NuvaRing lawsuits are pending in a Mass Tort proceeding in the Bergen County Superior Court of New Jersey (Docket No. BER-L-3081-09).
Alonso Krangle, LLP continues to offer free NuvaRing lawsuit evaluations to young women injured by NuvaRing, or their families. To discuss a potential claim with one of the experienced and compassionate NuvaRing side effect lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical malpractice, whistleblower actions, employment law, and consumer fraud cases. A leading law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and plans to open additional locations in New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.